Roche’s tumour-agnostic therapy Rozlytrek approved in EU
Therapy has been approved to treat advanced NTRK fusion-positive solid tumours
Read More
Tag: Tumour agnostic therapy
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
